Virpax Pharmaceuticals Overview
Virpax Pharmaceuticals (VRPX) has a ROE of 1320.61%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow1320.61%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for VRPX is 1320.61%. That is above the Healthcare sector average of 21.67%. Investors often review this figure alongside Virpax Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, VRPX currently prints 1320.61% for ROE, while the sector average sits near 21.67%. That is roughly 5994.7% above the sector mean. Large gaps often invite a closer look at Virpax Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Virpax Pharmaceuticals converts resources into returns. At 1320.61%, VRPX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VRPX's ROE (1320.61%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Virpax Pharmaceuticals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
